Siegfried Holding AG

As an internationally recognized outsourcing partner, Siegfried provides products and tailor made services that integrate seamlessly into a customer’s value chain. The company offers pharmaceutical industry partners a comprehensive range of services – from development of drug substances to product development, registration and manufacturing to packaging and logistics. Once a fully integrated pharmaceutical company, Siegfried is one of the few suppliers today that can provide both the drug substance and the drug product development and production capabilities. This combination of know-how and experience is unique for a supplier of development and production services.

Siegfried has expanded its technology base and geographic presence around the world in the past years. In addition to technological competence and a global presence, full compliance for all products and work processes to ensure safety is a high priority. The company adheres to the most rigorous requirements and quality guidelines in development, production and marketing. Siegfried’s reputation in this area is confirmed by a seamless performance record for audits – carried out by regulatory authorities and clients.

Its production facilities are located in Switzerland, the USA, Malta, China, Germany, France and Spain. In 2021, the company achieved net sales of CHF 1.1 billion and currently employs more than 3600 people. Siegfried Holding AG is publicly listed on the Swiss Stock Exchange in Zurich (SIX: SFZN).

Siegfried offers experience and proficiency in the chemical and pharmaceutical industry. Siegfried’s technology and capabilities include the development and production of APIs and finished dosage forms, making Siegfried the ideal partner for both cGMP and non-cGMP active pharmaceutical ingredients as well as the formulation of drug products.